Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Anti-PD-1 immunotherapy shows limited durable responses in many cancer patients.
• Identifying novel targets is crucial for improving anti-PD-1 efficacy.

Purpose of the Study:

• To identify targets that enhance anti-PD-1 immunotherapy response.
• To investigate the role of DDR2 in modulating anti-PD-1 treatment efficacy.

Main Methods:

• In vivo screening using a customized shRNA pooled library.
• Utilized isogenic in vivo murine models across five tumor histologies.
• RNA-sequencing (RNA-seq) and mass cytometry (CyTOF) analyses were performed.

Main Results:

• DDR2 depletion significantly increased sensitivity to anti-PD-1 treatment in multiple cancer types.
• Combination therapy with anti-PD-1 and dasatinib (a DDR2 inhibitor) reduced tumor load.
• DDR2 targeting, alone or with anti-PD-1, increased CD8+ T cell populations in tumors.

Conclusions:

• DDR2 is a key target for enhancing anti-PD-1 immunotherapy.
• Combining DDR2 inhibition with PD-1 blockade presents a promising therapeutic strategy for cancer treatment.